"uuid:ID","id","studyAcronym","studyTitle","versionIdentifier","rationale"
"bcad77d4-2484-4b77-8ede-375615a7052e","StudyVersion_1","LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
